<DOC>
	<DOCNO>NCT01826864</DOCNO>
	<brief_summary>This randomized phase III trial study sargramostim sentinel lymph node biopsy see well work compare hypertonic saline sentinel lymph node biopsy treat patient melanoma . Biological therapy , sargramostim , may stimulate immune system different way stop cancer cell grow . It yet know whether sargramostim effective hypertonic saline treat patient stage IB-II melanoma undergoing sentinel lymph node biopsy .</brief_summary>
	<brief_title>Sargramostim Hypertonic Saline Before Sentinel Lymph Node Biopsy Treating Patients With Stage IB-II Melanoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine alteration morphology phenotype sentinel lymph node reversible . II . To determine restoration morphology phenotype sentinel lymph node result diminish regional tumor burden . OUTLINE : Patients randomize 1 2 treatment arm . ARM I : Patients receive sargramostim subcutaneously ( SC ) 3-5 day prior undergoing sentinel lymph node biopsy . ARM II : Patients receive hypertonic saline SC 3-5 day prior undergoing sentinel lymph node biopsy . After completion study treatment , patient follow 30 day .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>Patients stage IB II cutaneous melanoma Primaries torso , upper low extremity head neck region Skin biopsy perform least 5 day longer 10 week time initial entry study Bilirubin &lt; 2.0 ng/dl Creatinine &lt; 3.0 ng/dl Able understand consent competent sign Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Prior wide excision diameter excision &gt; 3 cm Primary melanoma arise eye mucus membrane Clinical evidence regional , intransit , distant metastasis Second invasive melanoma Prior surgical procedure would alter drainage pattern would prevent u identify sentinel lymph node ( SN ) Patients primary secondary immunodeficiency Pregnancy Known allergy sargramostim ( GMCSF ) History cardiac disease , particular , supraventricular tachycardia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>